BioSante Pharma to license Melanoma Vaccine to Hussman Foundation
Under the deal, Hussman Foundation has paid $10,000 to BioSante and will further pay up to $39m in milestone payments and royalties on sales. Additionally, Hussman Foundation has
Harbour BioMed’s partner Solstice Oncology has raised $225m in funding to advance its lead candidate, porustobart, a neoadjuvant immuno-oncology therapy.